In September 2006, the International Association of Physicians in AIDS Care will mark a decade of highly active antiretroviral therapy. Has it really been 10 years since the so-called Protease Moment? KIRSTY MACHON reports on where we have come from – and where to from here.

HIV-related news in brief from the April 2006 edition of Positive Living.

Kivexa, a new single-pill combination of the antiviral drugs abacavir (Ziagen) and lamivudine (3TC) became available for S100 prescription from 1 December.

The HIV drug manufacturers Gilead Sciences, Bristol-Myers Squibb (BMS) and Merck have announced a joint venture to develop a single-pill, once-a-day HIV treatment.

With major medical conferences in the United States and Scotland, November was a busy month for HIV medicine. PAUL KIDD reviews some key findings.

Three of the biggest anti-HIV drug manufacturers have announced that they have commenced “early discussions” on developing the first licensed fixed-dose combination therapy incorporating drugs from more than one manufacturer.

We all want simpler treatment regimens with fewer side effects and no meal restrictions, right? Well how does once-a-day treatment sound? As PAUL KIDD reports, it may be closer than you think.